• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study.

作者信息

Sun Ruirui, Gou Yang, Pan Long, He Qiang, Zhou Yin, Luo Yi, Wu Chenrui, Zhao Yaowu, Fu Zixuan, Huang Ping

机构信息

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400000, China.

Department of Radiography, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400000, China.

出版信息

Cell Oncol (Dordr). 2024 Dec;47(6):2277-2278. doi: 10.1007/s13402-024-01031-8.

DOI:10.1007/s13402-024-01031-8
PMID:39718739
Abstract
摘要

相似文献

1
Correction to: Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study.对《肝动脉灌注化疗（HAIC）联合替雷利珠单抗和仑伐替尼治疗不可切除肝细胞癌：一项回顾性单臂研究》的更正
Cell Oncol (Dordr). 2024 Dec;47(6):2277-2278. doi: 10.1007/s13402-024-01031-8.
2
Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study.肝动脉灌注化疗（HAIC）联合替雷利珠单抗和仑伐替尼治疗不可切除肝细胞癌：一项回顾性单臂研究
Cell Oncol (Dordr). 2024 Dec;47(6):2265-2276. doi: 10.1007/s13402-024-01015-8. Epub 2024 Nov 25.
3
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗，联合或不联合经肝动脉栓塞术治疗伴有门静脉瘤栓和高肿瘤负荷的不可切除肝细胞癌：一项多中心回顾性研究
J Hepatocell Carcinoma. 2023 Jul 27;10:1209-1222. doi: 10.2147/JHC.S417550. eCollection 2023.
4
[Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma].肝动脉灌注化疗联合乐伐替尼和替雷利珠单抗治疗不可切除肝内胆管癌的初步临床应用
Zhonghua Nei Ke Za Zhi. 2024 Aug 1;63(8):769-775. doi: 10.3760/cma.j.cn112138-20231102-00287.
5
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.在高肿瘤负荷的不可切除肝细胞癌中，乐伐替尼和替雷利珠单抗对比阿替利珠单抗和贝伐单抗联合经动脉化疗栓塞性肝动脉灌注化疗：一项多中心回顾性队列研究
Cancer Immunol Immunother. 2025 Feb 1;74(3):88. doi: 10.1007/s00262-025-03942-3.
6
Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis.肝动脉灌注化疗联合乐伐替尼和替雷利珠单抗治疗高肿瘤负荷晚期肝细胞癌的有效性和安全性：一项多中心倾向评分匹配分析
Front Pharmacol. 2025 Jan 7;15:1499269. doi: 10.3389/fphar.2024.1499269. eCollection 2024.
7
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.肝动脉灌注化疗联合或不联合乐伐替尼治疗不可切除胆管癌：一项单中心回顾性研究
Hepat Oncol. 2023 Sep 29;10(2):HEP49. doi: 10.2217/hep-2023-0006. eCollection 2023 Jun.
8
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma.比较 PD-L1 与 PD-1 抗体联合仑伐替尼和肝动脉灌注化疗治疗不可切除的肝细胞癌。
Front Immunol. 2024 Oct 23;15:1491857. doi: 10.3389/fimmu.2024.1491857. eCollection 2024.
9
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗治疗伴Vp4门静脉侵犯的晚期肝细胞癌
Hepatol Int. 2025 Feb;19(1):106-117. doi: 10.1007/s12072-024-10762-7. Epub 2025 Jan 9.
10
Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌肝动脉灌注化疗联合或不联合仑伐替尼的疗效分析。
Eur Surg Res. 2023;64(2):268-277. doi: 10.1159/000529475. Epub 2023 Feb 22.

引用本文的文献

1
Systemic treatment of liver cancer: Current status and future perspectives.肝癌的系统治疗：现状与未来展望
World J Hepatol. 2025 Jul 27;17(7):107520. doi: 10.4254/wjh.v17.i7.107520.